ArticleEye (London, England)2026
Clinical outcomes of the PAUL® Glaucoma implant for refractory glaucoma: three-year results.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative In Vitro Evaluation of Tube Resistance in Glaucoma Drainage Devices with Intraluminal Polypropylene Threads.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report three-year outcomes undergoing PAUL® Glaucoma Implant (PGI) surgery in a single-centre cohort.
methodsA retrospective cohort study including patients undergoing PGI surgery at the University Eye Hospital Bonn, Germany, from April to September 2021. Patients were enrolled in a database at the time of surgery, with follow-up data collected at each visit. The primary outcome was the success rate based on predefined IOP criteria (A ≤ 21, B ≤ 18, C ≤ 15, and D ≤ 12 mmHg). Secondary outcomes included IOP, BCVA, IOP-lowering medications, complications, and intraluminal Prolene stent removal.
resultsSixty eyes of 56 patients were included. Qualified and complete success rates (95% CI) were 88% (80-97) and 43% (30-56) for Criterion A, 67% (53-78) and 37% (23-50) for Criterion B, 43% (30-57) and 27% (15-39%) for Criterion C and 30% (18-42) and 22% (12-33) for Criterion D. Mean IOP decreased from 26.73 mmHg (7-48) to 10.83 mmHg (4-20) (reduction of 54%) over 36 months with a reduction in IOP-lowering agents from 3.38 to 0.57. Three eyes developed hypotony requiring intervention, one required DMEK for corneal decompensation, and seven required conjunctival revision for tube exposure. The Prolene stent was removed in 29 eyes (49.2%) after a mean of 4.44 months, reducing IOP from 23.58 to 12.04 mmHg.
conclusionsPGI surgery effectively reduces IOP and medication burden in refractory glaucoma, with sustained efficacy over three years. The intraluminal Prolene stent enables further non-invasive IOP reduction postoperatively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.